Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early.

Business Wire • Dec 11, 2025

Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

Top 2 Health Care Stocks You May Want To Dump This Month

As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Dec 2, 2025

EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories

MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cash.

GlobeNewsWire • Nov 24, 2025

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12 in San Antonio, Texas. The data to be presented builds upon Exact Sciences' long-standing commitment to backing innovation with strong clinical evidence and commitment to equitable breast cancer care. This commitme.

Business Wire • Nov 24, 2025

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for each share of Exact Sciences that they own. KSF is seeking to determine whether this consideration and the proc.

Business Wire • Nov 22, 2025

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.

Investopedia • Nov 20, 2025

Is it too late to buy Exact Sciences stock after Abbott's $21B deal?

Exact Sciences (NASDAQ: EXAS) rallied nearly 20% on November 20 after Abbott Laboratories (NYSE: ABT) announced a $21 billion all-cash deal to acquire the molecular diagnostics company.

Invezz • Nov 20, 2025

Why Exact Sciences Rallied Over 50% This Week

Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs.

The Motley Fool • Nov 20, 2025

Why Exact Sciences Stock Surged Today

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer.

The Motley Fool • Nov 20, 2025